Zacks Research Weighs in on ResMed’s Q2 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Investment analysts at Zacks Research boosted their Q2 2025 earnings estimates for shares of ResMed in a research report issued to clients and investors on Tuesday, November 12th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $2.24 per share for the quarter, up from their prior estimate of $2.19. The consensus estimate for ResMed’s current full-year earnings is $9.22 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.27 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $9.06 EPS, Q2 2026 earnings at $2.32 EPS, Q3 2026 earnings at $2.47 EPS, Q4 2026 earnings at $2.48 EPS, FY2026 earnings at $9.52 EPS and FY2027 earnings at $10.46 EPS.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.17. The business had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.64 EPS.

Other equities analysts have also recently issued research reports about the company. KeyCorp boosted their target price on ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Royal Bank of Canada upped their price objective on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a report on Friday, October 25th. Robert W. Baird raised their target price on ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Baird R W upgraded shares of ResMed to a “strong-buy” rating in a research report on Tuesday, September 24th. Finally, Bank of America increased their price target on shares of ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $225.70.

ResMed Stock Performance

Shares of ResMed stock opened at $231.43 on Thursday. The firm’s fifty day simple moving average is $243.30 and its 200-day simple moving average is $223.37. ResMed has a 12 month low of $147.31 and a 12 month high of $260.49. The stock has a market capitalization of $33.97 billion, a price-to-earnings ratio of 30.65, a PEG ratio of 1.81 and a beta of 0.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be issued a dividend of $0.53 per share. The ex-dividend date is Thursday, November 7th. This represents a $2.12 annualized dividend and a dividend yield of 0.92%. ResMed’s dividend payout ratio is 28.08%.

Insider Buying and Selling

In related news, CFO Brett Sandercock sold 1,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $246.42, for a total transaction of $246,420.00. Following the completion of the transaction, the chief financial officer now directly owns 96,812 shares in the company, valued at $23,856,413.04. This represents a 1.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Witte Jan De sold 796 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total transaction of $198,052.76. Following the transaction, the director now directly owns 6,723 shares of the company’s stock, valued at $1,672,749.63. This represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,056 shares of company stock worth $15,086,020. Corporate insiders own 0.71% of the company’s stock.

Institutional Investors Weigh In On ResMed

Several large investors have recently made changes to their positions in RMD. Bank of New York Mellon Corp raised its holdings in ResMed by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,772,761 shares of the medical equipment provider’s stock worth $1,105,022,000 after purchasing an additional 1,959,642 shares during the last quarter. Marshall Wace LLP bought a new stake in ResMed in the 2nd quarter valued at $77,285,000. Greenvale Capital LLP raised its holdings in shares of ResMed by 61.1% in the second quarter. Greenvale Capital LLP now owns 725,000 shares of the medical equipment provider’s stock valued at $138,780,000 after purchasing an additional 275,000 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec grew its position in ResMed by 726.3% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 283,801 shares of the medical equipment provider’s stock valued at $69,281,000 after purchasing an additional 249,454 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its position in shares of ResMed by 48.3% during the 2nd quarter. Los Angeles Capital Management LLC now owns 740,226 shares of the medical equipment provider’s stock worth $141,694,000 after purchasing an additional 241,195 shares during the last quarter. Institutional investors own 54.98% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.